Kohlberg Kravis Roberts & Co’s AEON Biopharma AEON Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-308	Closed	-$223K	–	84
2022 Q4	$223K	Hold	308	–	–	0.01%	110
2022 Q3	$219K	Hold	308	–	–	﹤0.01%	166
2022 Q2	$218K	Hold	308	–	–	﹤0.01%	200
2022 Q1	$217K	Buy	308 +162	+111%	+$114K	﹤0.01%	211
2021 Q4	$102K	Buy	+146	New	+$103K	﹤0.01%	185

Other funds holding AEON

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

GCWM

Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's AEON Position: Q1 2023 in Review

Kohlberg Kravis Roberts & Co sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 308 shares — an estimated $223K sold.

Kohlberg Kravis Roberts & Co first reported a position in AEON in Q4 2021 and held it in 5 quarters. The position peaked at $223K in Q4 2022. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

Kohlberg Kravis Roberts & Co reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
Kohlberg Kravis Roberts & Co sold 308 AEON Biopharma shares in Q1 2023, an estimated $223K.
Kohlberg Kravis Roberts & Co first reported a position in AEON Biopharma in Q4 2021 and held it in 5 quarters.
Kohlberg Kravis Roberts & Co's AEON Biopharma position peaked at $223K in Q4 2022.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q1 2023, filed 15 May 2023.